Cite
HARVARD Citation
Goy, A. et al. (2016). A phase 2 study of inotuzumab ozogamicin in patients with indolent B‐cell non‐Hodgkin lymphoma refractory to rituximab alone, rituximab and chemotherapy, or radioimmunotherapy. British journal of haematology. pp. 571-581. [Online].